Diabetes News Archive

Category: Items & Merchandise User : Riz Date : Wednesday, 30/06/10 - 12:38PM Description : Title: Diabetes Cookbook. 2008 published by Reader's Digest Category: Cooking Overview: From baked breakfast delights and fresh salads to succulent stews and delectable desserts, the DIABETES COOKBOOK shows you how to eat the most flavourful and satisfying dishes while managing your diabetes at the same ...

The diabetes drug Avandia is back on the hot seat this week, with two new studies published Monday suggesting that it may increase the risk of heart attack and other cardiovascular problems.

Patients aged at least 65 years who have diabetes type 2 and take Avandia (Rosiglitazone) have a higher risk of developing stroke, heart failure, and even dying compared to similar patients who take Actos (Pioglitazone), according to a new study published in JAMA (Journal of the American Medical Association). Pioglitazone is also known as Glustin in non-UK Europe, Glizone and Pioz in India and ...

Rosiglitazone, a commonly used diabetes drug, poses no significant increased risk of death, stroke or heart attack, though it does increase the risk of fractures, according to a new analysis of thousands of patients with established cardiovascular disease and type 2 diabetes. The findings are being presented at the American Diabetes Association's 70th Scientific Sessions®, and are part of the ...

The diabetes drug Avandia used to be a s3.4 billion-a-year blockbuster. Then some studies strongly suggested people taking it have a higher risk of heart attacks. Two new studies, one from the FDA, nail down the risk -- just as the FDA is getting ready to decide whether Avandia should be taken off...

The diabetes drug Avandia used to be a $3.4 billion-a-year blockbuster. Then some studies strongly suggested people taking it have a higher risk of heart attacks. Two new studies, one from the FDA, nail down the risk -- just as the FDA is getting ready to decide whether Avandia should be taken off the market.

The diabetes drug Avandia used to be a $3.4 billion-a-year blockbuster. Then some studies strongly suggested that people taking it have a higher risk of heart attacks. Two new studies, one from the FDA, nail down the risk -- just as the FDA is getting ready to decide whether Avandia should be taken off the market.